The NIH funding significantly de-risks MAIA's U.S. clinical development program. Traders should monitor patient enrollment rates at the new U.S. sites and watch for upcoming efficacy data readouts that could support future regulatory submissions. The Fast Track designation improves the probability of approval.
Price Chart
Executive Summary
MAIA Biotechnology announced the activation of its first U.S. clinical site for the Phase 2 THIO-101 expansion trial of ateganosine, a novel telomere-targeting therapy for advanced non-small cell lung cancer (NSCLC). The trial expansion is funded by a $2.3 million NIH grant and marks a key milestone in the company's clinical development program.
Key Facts
- Activated first U.S. site (Summit Medical Group in New Jersey) for Phase 2 THIO-101 trial of ateganosine in advanced NSCLC
- Trial expansion funded by $2.3 million grant from the National Institutes of Health (NIH)
- MAIA plans to open four additional U.S. sites in 2026
- Trial ongoing in 44 sites across 6 countries in Europe and Asia
- Company holds FDA Fast Track designation for its lead drug targeting advanced NSCLC
- 2025 data showed exceptional efficacy with overall survival beyond two years in eight patients
Financial Impact
The trial expansion is funded by a $2.3 million NIH grant, reducing the company's financial burden for U.S. clinical development costs
Risk Factors
- Clinical trial may not demonstrate sufficient efficacy in larger patient populations
- Safety issues could emerge in expanded trial
- Regulatory approval is not guaranteed despite Fast Track designation
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-016989 |
| Exhibit: ex99-1.htm | 0001493152-26-016989 |
| Document: 0001493152-26-016989-index-headers.html | 0001493152-26-016989 |
| Document: 0001493152-26-016989-index.html | 0001493152-26-016989 |
| Document: 0001493152-26-016989.txt | 0001493152-26-016989 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 7, 2026 20d ago | EFFECT | $1.18 | awaiting T+60 | — | $1.17 (+0.85%) |
Oct 6, 2026 21d ago | 8-K | $1.19 | awaiting T+60 | — | $1.17 (−1.68%) |
Sep 25, 2026 4w ago | S-3 | $1.18 | awaiting T+60 | — | $1.17 (+0.85%) |
Sep 16, 2026 5w ago | Press Release | $1.40 | awaiting T+60 | — | $1.17 (−16.43%) |
Sep 15, 2026 6w ago | Press Release | $1.34 | awaiting T+60 | — | $1.17 (−12.69%) |
Sep 15, 2026 6w ago | Insider Cluster | $1.34 | awaiting T+60 | — | $1.17 (−12.69%) |
Jun 3, 2026 20w ago | Press Release | $1.43 $1.38 | ▼ −3.50% | ▼ −6.00% | $1.17 (−18.18%) |
Jun 2, 2026 21w ago | Insider Cluster | $1.35 $1.39 | ▲ +2.96% | ▲ +1.85% | $1.17 (−13.33%) |
May 19, 2026 23w ago | DEFA14A | $1.23 $1.34 | ▲ +8.94% | ▲ +2.65% | $1.17 (−4.88%) |
May 14, 2026 23w ago | 8-K | $1.26 $1.38 | ▲ +9.52% | ▲ +5.01% | $1.17 (−7.14%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers